True or False: The cobas® EGFR Mutation Test v2 has been approved by the FDA to detect EGFR mutations in non-small cell lung cancer (NSCLC) patients, as an aid in selecting therapy with an EGFR tyrosine kinase inhibitor (TKI).
Select true or false